Combinational therapy is usually considered as a preferable approach for effective cancer therapy. Especially, combinational chemotherapies targeting different molecular targets are of particular interest due to its high flexibility as well as efficiency. In our study, the surface of silica nanoparticles (SLN) was modified with low-density lipoprotein (LDL) to construct platform (LDL-SLN) capable of specifically targeting low-density lipoprotein receptors (LDLRs) that overexpressing in hepatocellular carcinoma (HCC). In addition, the versatile drug loading capacity of LDL-SLN was employed to fabricate a preferable drug delivery system to co-deliver sorafenib (Sor) and doxorubicin (Dox) for combinational chemotherapy of HCC. Our results revealed that the LDL-SLN/Sor/Dox nanoparticles with size around 100 nm showed preferable stability in physiological environments. Moreover, the LDL-SLN/Sor/Dox could target LDLR overexpressed HepG2 cells. More importantly, both in vitro and in vivo experiments demonstrated that the LDL-SLN/Sor/Dox exerted elevated antitumor efficacy compared to Sor or Dox alone, which indicated that LDL-SLN/Sor/Dox could be a powerful tool for effective combinational chemotherapy of HCC.

中文翻译：

---

低密度脂蛋白修饰的二氧化硅纳米粒子共同递送索拉非尼和阿霉素，有效治疗肝细胞癌。

联合治疗通常被认为是有效癌症治疗的优选方法。特别是，针对不同分子靶点的联合化疗因其高度灵活性和效率而受到特别关注。在我们的研究中，用低密度脂蛋白（LDL）修饰二氧化硅纳米颗粒（SLN）的表面，构建能够特异性靶向肝细胞癌（HCC）中过度表达的低密度脂蛋白受体（LDLR）的平台（LDL-SLN） 。此外，利用LDL-SLN的多功能载药能力来制造更好的药物递送系统，共同递送索拉非尼（Sor）和阿霉素（Dox）用于HCC联合化疗。我们的结果表明，尺寸约为 100 nm 的 LDL-SLN/Sor/Dox 纳米颗粒在生理环境中表现出较好的稳定性。此外，LDL-SLN/Sor/Dox 可以靶向 LDLR 过表达的 HepG2 细胞。更重要的是，体外和体内实验均表明，与单独使用Sor或Dox相比，LDL-SLN/Sor/Dox具有更高的抗肿瘤功效，这表明LDL-SLN/Sor/Dox可能成为有效联合化疗的有力工具。肝癌。